Livzon Pharma's 3-Month Leuprorelin Acetate Microspheres 11.25mg Wins Supplementary Drug Application Approval

Stock News
Sep 29

Livzon Pharma (01513) has announced that its controlling subsidiary, Shanghai Livzon Pharmaceutical Co., Ltd. (Shanghai Livzon), recently received the "Drug Supplementary Application Approval Notice" (Certificate No.: 2026B06648) issued by the National Medical Products Administration, granting market approval for the leuprorelin acetate microspheres for injection 11.25mg (3-month formulation) produced by Shanghai Livzon.

The leuprorelin acetate microspheres for injection is a Class B product listed in the "National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug Catalog." The indications for the 3-month formulation include: (1) premenopausal breast cancer; (2) prostate cancer; (3) central precocious puberty.

The leuprorelin acetate microspheres for injection (3-month formulation) is administered via subcutaneous injection once every 12 weeks, distinguishing it from the already marketed 3.75mg 1-month formulation. The 3-month formulation differs in formulation process, quality standards, dosage and administration, and indications. The 3-month formulation uses a completely different core excipient, poly-DL-lactide, offering the advantages of longer duration of action and fewer administrations. After injection, it maintains stable blood drug concentrations for 12 weeks, with more stable release behavior, significantly reducing the blood drug concentration fluctuations associated with repeated administration of the 1-month formulation. This alleviates patient suffering and medication burden while improving drug tolerability and accessibility.

Poly-DL-lactide is a high-molecular-weight excipient independently developed by Shanghai Livzon and serves as the core excipient controlling microsphere release. Following the successful associated review this time, the registration status of this excipient has been changed to "A." After PLGA7525, poly-DL-lactide is the company's second approved polymer, further enhancing the company's competitiveness in microsphere technology research and development.

As of the disclosure date of this announcement, the cumulative direct R&D expenses invested in leuprorelin acetate microspheres for injection (3-month formulation) amount to approximately RMB 94.0548 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10